Patrova Jekaterina, Mannheimer Buster, Larsson Martin, Lindh Jonatan D, Falhammar Henrik
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 118 83 Stockholm, Sweden.
Department of Endocrinology, Södersjukhuset, 118 83 Stockholm, Sweden.
J Endocr Soc. 2024 Sep 13;8(10):bvae154. doi: 10.1210/jendso/bvae154. eCollection 2024 Aug 27.
It is unclear if nonfunctional adrenal tumors (NFAT) are associated with higher cancer incidence.
To analyze the cancer incidence in patients with NFAT.
In this national register-based retrospective cohort study, consecutive patients with NFAT identified in Sweden 2005-2019 and matched control individuals without adrenal tumors were followed up to 15 years. Outcome data were collected from national registers and adjusted for confounders. Both cases and controls were followed until newly diagnosed malignancy, death, or until 2019. Individuals with adrenal hormonal excess or prior malignancy were excluded.
Among 17 726 cases, 10 777 (60.8%) were women, and the median age was 65 (IQR, 57-73) years. Among 124 366 controls, 69 514 (55.9%) were women, and the median age was 66 (IQR, 58-73) years. The incidence of any cancer was higher in patients with NFAT compared to controls (hazard ratio [HR] 1.35 95% CI 1.29-1.40; adjusted HR 1.31, 95% CI 1.26-1.37). NFAT was associated with a higher incidence of adrenal, thyroid, lung, stomach and small intestine, kidney, pancreatic, breast, and colorectal cancer. Sensitivity analyses did not change the overall results, but associations were not significantly increased after adjustment in patients with NFAT and appendicitis or gallbladder/biliary tract/pancreas disorders. Cancer incidence may have been underestimated by adjusting for unclear and benign tumors.
The incidence of cancer was increased in patients with NFAT. Long-term follow-up may be indicated.
尚不清楚无功能肾上腺肿瘤(NFAT)是否与较高的癌症发病率相关。
分析NFAT患者的癌症发病率。
在这项基于全国登记的回顾性队列研究中,对2005年至2019年在瑞典确定的连续NFAT患者以及匹配的无肾上腺肿瘤对照个体进行了长达15年的随访。结局数据从国家登记处收集,并对混杂因素进行了调整。病例组和对照组均随访至新诊断出恶性肿瘤、死亡或直至2019年。排除肾上腺激素过多或既往有恶性肿瘤的个体。
在17726例病例中,10777例(60.8%)为女性,中位年龄为65岁(四分位间距,57 - 73岁)。在124366例对照中,69514例(55.9%)为女性,中位年龄为66岁(四分位间距,58 - 73岁)。与对照组相比,NFAT患者的任何癌症发病率更高(风险比[HR] 1.35,95%置信区间1.29 - 1.40;调整后HR 1.31,95%置信区间1.26 - 1.37)。NFAT与肾上腺、甲状腺、肺、胃和小肠、肾、胰腺、乳腺和结直肠癌的较高发病率相关。敏感性分析未改变总体结果,但在调整NFAT合并阑尾炎或胆囊/胆道/胰腺疾病的患者后,关联未显著增加。通过对不明和良性肿瘤进行调整,癌症发病率可能被低估了。
NFAT患者的癌症发病率增加。可能需要进行长期随访。